title: Long-term results after aortic valve replacement in patients with congestive heart failure. Homografts vs prosthetic valves.
abstract: OBJECTIVE
  The aim of this study was to assess the influence of valve substitute (homograft vs prosthetic valve) on the long-term survival and late valve-related complication rates following aortic valve replacement in patients with aortic valve disease and congestive heart failure.
  
  
  BACKGROUND
  The effect of choice of valve substitute on outcome after aortic valve replacement in patients with pre-operative heart failure is unknown. The superior haemodynamic profile of homografts may be of particular benefit.
  
  
  METHODS
  We retrospectively analysed pre-operative, operative and follow-up data on 518 adults in functional classes III and IV, who, over the 25 years 1969-1993, had their initial aortic valve replacement at Harefield hospital. Follow-up conducted during 1996 to April 1997 and totalling 4439 patient-years was 96.1% complete. Using multivariate analysis, independent risk factors for different complications and mortality were defined.
  
  
  RESULTS
  Overall 5-, 10- and 20-year survival was 80+/-2%, 62+/-2% and 30+/-3%, respectively, with no significant difference between valve types. However, homografts (n=381) independently reduced the rate of serious complications and cardiac death, whereas mechanical valves were an independent adverse risk factor for late mortality. The rates of anticoagulant-related bleeding and thromboembolism were increased by mechanical valves, whereas primary tissue failure was the main complication of homografts.
  
  
  CONCLUSIONS
  Long-term outcome of homograft aortic valve replacement in patients with congestive heart failure is acceptable, with a reduced rate of serious complications and cardiac death. Further improvements would be expected if the rate of primary tissue failure could be reduced.
authors.affiliation: Department of Cardiology and Academic Department of Cardiac Surgery, Harefield Hospital, Harefield, Middlesex, U.K.
authors.forename: R M
authors.initials: RM
authors.lastname: Grocott-Mason
authors.forename: O
authors.initials: O
authors.lastname: Lund
authors.forename: H
authors.initials: H
authors.lastname: Elwidaa
authors.forename: R
authors.initials: R
authors.lastname: Mazhar
authors.forename: V
authors.initials: V
authors.lastname: Chandrasakeran
authors.forename: A G
authors.initials: AG
authors.lastname: Mitchell
authors.forename: C
authors.initials: C
authors.lastname: Ilsley
authors.forename: A
authors.initials: A
authors.lastname: Khaghani
authors.forename: A
authors.initials: A
authors.lastname: Rees
authors.forename: M
authors.initials: M
authors.lastname: Yacoub
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery* / Q000637:transplantation*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000592:standards; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000592:standards